Overview

Webcast ImageWebcast
Q3 2014 Laboratory Corporation of America Holdings Earnings Conference Call  (Live)
10/28/14 at 9:00 a.m. ET
Corporate Profile

Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.8 billion in 2013, over 34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technolo... More >>

Recent NewsMore >>
DateTitle 
10/15/14LabCorp’s Acquisition of LipoScience Clears Antitrust Approval
BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 15, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of LipoScience, Inc. (NASDAQ: LPDX) by LabCorp. Early termination of the waiting period satisfies one of the conditions necessary t... 
Printer Friendly Version
10/01/14Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 1, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version
09/25/14LabCorp Announces Agreement to Acquire LipoScience
Acquisition Price of $5.25 Per Share in All Cash Transaction NMR LipoProfile test expands LabCorp’s offering of personalized diagnostic tests BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 25, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) and LipoScience, Inc. (NASDAQ:LPDX), a provider of specialized cardiovascular diagnostic laboratory tests based on nuclear magnetic resonance (NMR) technology, today announce... 
Printer Friendly Version
09/12/14LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 12, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of September 12, 2014 to March 11, 2015, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
10/28/14
Q3 2014 Laboratory Corporation of America Holdings Earnings Conference Call
LH (Common)
ExchangeNYSE
Price$98.01
Change Stock is Down 0.26
Intraday High$98.26
Intraday Low$96.51
Volume826,271
Data as of 10/16/14
4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Reports & Performance

2013 Annual Report

2012 Annual Report

2011 Annual Report

2010 Annual Report

2009 Annual Report

2008 Annual Report

2007 Annual Report

2006 Annual Report

Latest Earnings Release